GREENLIGHT CAPITAL RE LTD
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Segment Reporting
- SEGMENT REPORTING
For the quarter and year ended December 31, 2024, the Company has amended its reportable segments as follows:
Open Market
In the Open Market segment, the Company underwrites reinsurance business, sourced through the brokerage distribution channels and Lloyd’s. The Company writes mostly treaty reinsurance, on a proportional and non-proportional basis. The lines of business for this segment are as follows: Casualty, Financial, Health, Multiline, Property and Specialty.
Innovations
In the Innovations segment, the Company provides reinsurance capacity to startup companies and MGAs based globally, sourced mainly through direct placements with its strategic partners (see Note 4). This segment also includes business written by Syndicate 3456. The lines of business for this segment are as follows: Casualty, Financial, Health, Multiline and Specialty.
The Company’s reportable segments each have executive leadership who are responsible for their performance and who are directly accountable to the CODM. The change in reportable segments was driven by the appointment of a new CEO, who is the CODM. The CODM reviews the financial performance of the reportable segment to assess the achievement of strategic initiatives, the efficiency of the deployed capital, and how to allocate resources to the reportable segments based on the segment’s financial performance.
In addition to its reportable segments, the Company has a Corporate category included in the below tables, which includes runoff business (see Note 7), corporate expenses, income from investment in Solasglas, foreign exchange gains (losses), interest expense and income taxes.
The table below provides information about the Company’s reportable segments, including the reconciliation to net income as reported under U.S. GAAP. Comparatives have been recast to conform with the new reportable segments.
| Year ended December 31, 2024: · Open Market · Innovations · Corporate · Total Consolidated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Gross premiums written | $603,798 | $94,725 | $(188) | $698,335 | ||||
| Net premiums written | 541,446 | 80,016 | (197) | 621,265 | ||||
| Net premiums earned | 511,922 | 86,352 | 21,680 | 619,954 | ||||
| Net loss and LAE incurred | (341,586) | (51,939) | (33,744) | (427,269) | ||||
| Acquisition costs | (144,852) | (27,151) | (4,772) | (176,775) | ||||
| Other underwriting expenses | (19,175) | (3,682) | — | (22,857) | ||||
| Deposit interest expense, net (1) | (1,228) | — | — | (1,228) | ||||
| Underwriting income (loss) | 5,081 | 3,580 | (16,836) | (8,175) | ||||
| Reconciliation to income before income taxes: | ||||||||
| Net investment income | 42,629 | 702 | 2,623 | 45,954 | ||||
| Corporate and other expenses | — | (2,445) | (13,932) | (16,377) | ||||
| Income from investment in Solasglas | 33,605 | 33,605 | ||||||
| Foreign exchange gains (losses) | (5,606) | (5,606) | ||||||
| Interest expense | (5,836) | (5,836) | ||||||
| Income before income taxes | $47,710 | $1,837 | $(5,982) | $43,565 | ||||
| Additional information: | ||||||||
| Net loss and LAE incurred: | ||||||||
| Attritional losses | $290,961 | $52,235 | $5,780 | $348,976 | ||||
| CAT losses | 35,681 | — | $21,808 | $57,489 | ||||
| Prior year adverse (favorable) loss development | 14,944 | (296) | $6,156 | $20,804 | ||||
| Total net loss and LAE incurred | $341,586 | $51,939 | $33,744 | $427,269 | ||||
| Total allocated assets (2) | $454,647 | $110,119 | $1,451,457 | $2,016,223 | ||||
(1) For the purpose of the above reportable segments table, the Company has reclassified $2.1 million of deposit interest income from “Other income, net” to “Deposit interest expense, net” relating to reinsurance contracts that did not meet the risk transfer requirement under U.S. GAAP.
(2) The Company does not allocate assets to reporting segments, with the exception of restricted cash used to collateralized certain reinsurance transactions, including FAL, and Innovations-related private investments.
| Year ended December 31, 2023: · Open Market · Innovations · Corporate · Total Consolidated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Gross premiums written | $504,435 | $88,602 | $43,773 | $636,810 | ||||
| Net premiums written | 466,544 | 83,608 | 43,896 | 594,048 | ||||
| Net premiums earned | 466,751 | 71,769 | 44,627 | 583,147 | ||||
| Net loss and LAE incurred | (262,290) | (44,855) | (52,859) | (360,004) | ||||
| Acquisition costs | (136,356) | (22,381) | (10,140) | (168,877) | ||||
| Other underwriting expenses | (16,827) | (2,760) | — | (19,587) | ||||
| Deposit interest expense, net | (2,687) | — | — | (2,687) | ||||
| Underwriting income (loss) | 48,591 | 1,773 | (18,372) | 31,992 | ||||
| Reconciliation to income before income taxes: | ||||||||
| Net investment income | 37,351 | 2,732 | 3,325 | 43,408 | ||||
| Corporate and other expenses | — | (3,080) | (20,573) | (23,653) | ||||
| Income from investment in Solasglas | 28,696 | 28,696 | ||||||
| Foreign exchange gains (losses) | 11,566 | 11,566 | ||||||
| Other income, net | 265 | 265 | ||||||
| Interest expense | (5,344) | (5,344) | ||||||
| Income before income taxes | $85,942 | $1,425 | $(437) | $86,930 | ||||
| Additional information: | ||||||||
| Net loss and LAE incurred: | ||||||||
| Attritional losses | $243,440 | $44,425 | $32,162 | $320,027 | ||||
| CAT losses | 15,264 | — | 13,507 | 28,771 | ||||
| Prior year adverse (favorable) loss development | 3,586 | 430 | 7,190 | 11,206 | ||||
| Total net loss and LAE incurred | $262,290 | $44,855 | $52,859 | $360,004 | ||||
| Total allocated assets (2) | $485,388 | $98,467 | $1,151,451 | $1,735,307 | ||||
(2) The Company does not allocate assets to reporting segments, with the exception of restricted cash used to collateralized certain reinsurance transactions, including FAL, and Innovations-related private investments.
| Year ended December 31, 2022: · Open Market · Innovations · Corporate · Total Consolidated | |||||||
|---|---|---|---|---|---|---|---|
| Gross premiums written | $452,541 | $50,739 | $59,891 | $563,171 | |||
| Net premiums written | 437,799 | 47,328 | 44,615 | 529,742 | |||
| Net premiums earned | 410,877 | 33,184 | 25,416 | 469,477 | |||
| Net loss and LAE incurred | (268,659) | (23,151) | (24,675) | (316,485) | |||
| Acquisition costs | (125,296) | (11,111) | (6,741) | (143,148) | |||
| Other underwriting expenses | (11,867) | (1,946) | — | (13,813) | |||
| Deposit interest expense, net | (6,717) | — | — | (6,717) | |||
| Underwriting income (loss) | (1,662) | (3,024) | (6,000) | (10,686) | |||
| Reconciliation to income before income taxes: | |||||||
| Net investment income | 4,898 | 9,869 | (6,417) | 8,350 | |||
| Corporate and other expenses | — | (3,452) | (14,341) | (17,793) | |||
| Income from investment in Solasglas | 54,844 | 54,844 | |||||
| Foreign exchange gains (losses) | (5,988) | (5,988) | |||||
| Interest expense | (4,201) | (4,201) | |||||
| Income before income taxes | $3,236 | $3,393 | $17,897 | $24,526 | |||
| Additional information: | |||||||
| Net loss and LAE incurred: | |||||||
| Attritional losses | $235,179 | $20,482 | $20,989 | $276,650 | |||
| CAT losses | 36,967 | 0 | 2,750 | 39,717 | |||
| Prior year adverse (favorable) loss development | (3,487) | 2,669 | 936 | 118 | |||
| Total net loss and LAE incurred | $268,659 | $23,151 | $24,675 | $316,485 | |||
| Total allocated assets (2) | $631,738 | $84,516 | $864,127 | $1,580,381 | |||
(2) The Company does not allocate assets to reporting segments, with the exception of restricted cash used to collateralized certain reinsurance transactions, including FAL, and Innovations-related private investments.
The other underwriting expenses includes general and administrative expenses directly attributable to each of the segment, in addition to allocated indirect overhead costs.
The net investment income includes:
Interest income earned on restricted cash (see Note 5 -Restricted Cash and Cash Equival ents) and FAL balances directly attributable to each of the segments; and
Realized and unrealized gains (losses) on private investments directly attributable to Innovations segment (see Note 4 -Other Investments).
The Company had no intersegment revenues for the years ended December 31, 2024, 2023, and 2022.
Concentration of revenue
The Company has a diverse client base, for which there was no individual customer that accounted for more than 10% of the total consolidated gross premiums written for the years ended December 31, 2024, 2023, and 2022.
Premiums by Geographic Area
The following table presents gross premiums written by the geographical location of the Company’s subsidiaries:
| Year ended December 31, · 2024 · 2023 · 2022 | ||||||
|---|---|---|---|---|---|---|
| Ireland | $160,736 | 23.0% | $95,371 | 15.0% | $246,637 | 43.8% |
| United Kingdom | 176,336 | 25.3 | 192,699 | 30.3 | — | — |
| Cayman Islands | 361,263 | 51.7 | 348,740 | 54.7 | 316,534 | 56.2 |
| $698,335 | 100.0% | $636,810 | 100.0% | $563,171 | 100.0% | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.